457_537
601_774
844_898
1425_1747
1756_1976
1985_2400
The primary endpoint of the study is the change from baseline in the UAS7 (Urticaria Activity Score over 7 Days) at Week 12 The trial is planned to be conducted across multiple sites in Asia and Europe, including South Korea, Japan
2682_2967
2976_3520
3529_3956
3965_4315
4324_4764
4773_5174
5183_5510